McGowan, C. R.
Wright, T.
Nitsch, D.
Lewer, D.
Brathwaite, R.
Scott, J.
Hope, V.
Ciccarone, D.
Dunn, J.
Gillmore, J.
Story, A.
Harris, M.
Article History
Received: 18 December 2019
Accepted: 30 March 2020
First Online: 27 April 2020
Competing interests
: Dr. McGowan reports personal fees from European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) outside the submitted work. Dr. Nitsch reports other grants from Glaxo Smith Kline, outside the submitted work. Dr. Scott reports other from Turning Point, other from Cognisant Research, non-financial support from Academy of Medical Sciences, grants from Medical Research Council, grants from Pharmacy Research UK, outside the submitted work. Dr. Ciccarone reports grants from the US National Institutes of Heath, National Institute on Drug Abuse, during the conduct of the study; personal fees from Malinckrodt, personal fees from Nektar Therapeutics, personal fees from Celero Systems, personal fees from American Association for the Advancement of Science, outside the submitted work. The remaining authors declare no competing interests.